The short answer
Attaching a fatty acid chain lets a peptide bind reversibly to serum albumin. The bound complex is too large for kidney filtration and is shielded from proteases, while a small free fraction stays available to the receptor. Chain length tunes the result: C16 gives daily dosing, C18 and C20 diacids give weekly.
Key facts
- Mechanism
- Reversible binding to serum albumin
- Blocks
- Glomerular filtration and proteolysis
- Liraglutide
- C16 palmitic: ~13 h, daily
- Semaglutide
- C18 diacid + γGlu-2xOEG: ~1 week
- Retatrutide
- C20 diacid at Lys17: weekly
- Why reversible
- A permanently bound peptide could not act
- Albumin half-life
- About 19 days
The problem being solved
A peptide of incretin size is small enough to pass the glomerulus and be excreted, and exposed enough to be cleaved by circulating proteases. Blocking DPP-4 with a substitution at position 8 handles one enzyme; it does nothing about renal clearance. Something has to make the molecule effectively larger without changing what the receptor sees.
Why albumin is the obvious carrier
Serum albumin is the most abundant plasma protein, has a half-life of about 19 days, and evolved to bind fatty acids and transport them through the circulation. A peptide carrying a fatty acid chain therefore has a ready-made, high-capacity, long-lived carrier already present in the blood. Nothing has to be co-administered.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Why the binding must be reversible
This is the part that makes the design work. A peptide permanently bound to a 66 kDa protein could not engage its receptor; it would be protected and useless. Because binding is an equilibrium, a small free fraction exists at any moment and is available to signal, while the bound pool acts as a slow-release depot that continuously replenishes it. The effective half-life reflects the whole pool, not the free fraction.
How chain length tunes the result
Longer and more lipophilic chains bind albumin more tightly, shifting the equilibrium toward the bound state and extending half-life. Liraglutide's C16 palmitic acid gives roughly 13 hours, enough for daily dosing. Semaglutide's C18 diacid, attached through a γGlu-2xOEG linker, gives about a week. Retatrutide uses a C20 diacid at Lys17 through the same linker chemistry. Same strategy, three intensities.
What the linker does
The γGlu-2xOEG spacer between peptide and fatty acid is not inert padding. It sets the distance and flexibility between the albumin-binding element and the receptor-binding peptide, so that albumin binding does not sterically block the peptide from reaching its receptor. Getting the linker wrong can compromise either binding event.
Why this recurs across compounds targeting different receptors
Semaglutide targets GLP-1R. Tirzepatide targets GIPR and GLP-1R. Retatrutide adds the glucagon receptor. Their receptor pharmacology differs completely, yet all three carry a fatty diacid on a lysine through a similar linker, because they share a clearance problem rather than a target. Recognising that explains the structural family resemblance across molecules that otherwise have little in common.
Quick reference
| Compound | Lipid | Approx. half-life | Dosing |
|---|---|---|---|
| Native GLP-1 | None | 1-2 minutes | - |
| Liraglutide | C16 palmitic | ~13 hours | Daily |
| Semaglutide | C18 diacid | ~1 week | Weekly |
| Tirzepatide | C20 diacid | ~5 days | Weekly |
| Retatrutide | C20 diacid | Multi-day | Weekly (trials) |
Frequently asked questions
Why not just make the peptide bigger?
Size changes how the receptor sees it. Albumin binding adds effective size in circulation while leaving the receptor-binding portion unchanged.
Does the bound peptide work?
Not while bound. Binding is reversible, so a small free fraction is always available and the bound pool acts as a depot replenishing it.
Do small molecules need this?
No. Orforglipron and aleniglipron are cleared differently and are not peptides, so neither protease protection nor albumin binding applies.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- What Is Pramlintide? The First Clinical Amylin AnaloguePramlintide solved amylin's aggregation problem with three prolines borrowed from rat amylin. Why it needed meal-time dosing and cagrilintide does not.
- What Is Oxyntomodulin? Nature's Dual AgonistOxyntomodulin is a gut peptide that activates both GLP-1 and glucagon receptors. It is the biological precedent every GLP-1/glucagon dual agonist is built on.
- GLP-1 Agonists and Alcohol Use: The Trial EvidenceThree randomised trials have tested semaglutide in alcohol use disorder, reporting reduced craving and heavy drinking days. All were small and short.
- SURMOUNT-OSA: Tirzepatide in Obstructive Sleep ApnoeaTirzepatide reduced apnoea-hypopnoea index by 27.4 events per hour at 52 weeks against 4.8 on placebo. The first incretin approved for a non-metabolic use.
- Why GLP-1 Receptors Turn Up in Reward ResearchGLP-1 receptors are expressed in mesolimbic reward circuitry, not only in appetite regions. That expression is the mechanistic basis for the craving findings.